Table 1 Patient Characteristics by Cystic Fibrosis Transmembrane Regulator Mutation Status
From: A survey identifying nutritional needs in a contemporary adult cystic fibrosis cohort
|  | All Eligible Patients N = 66 | CFTR Mutation Class I-III N = 54 | CFTR Mutation Class IV-V N = 12 |  | |||
|---|---|---|---|---|---|---|---|
Variable | Observed | N | Observed | N | Observed | N | p Value |
Age – mean (SD), years | 32.3 (11.4) | 66 | 30.4 (8.8) | 54 | 40.8 (17.2) | 12 | 0.0637 |
Male gender | 32 (48.5) | 66 | 27 (50.0) | 54 | 5 (41.7) | 12 | 0.601 |
Medicaid Insurance | 23 (35.4) | 65 | 17 (32.1) | 53 | 6 (50.0) | 12 | 0.241 |
CFTR mutation status | Â | 66 | Â | Â | Â | Â | Â |
Homozygous Class I-III | 54 (81.8) | Â | Â | Â | Â | Â | Â |
Heterozygous Class I-III | 12 (18.2) | Â | Â | Â | Â | Â | Â |
Homozygous Class IV-V | 0 (0) | Â | Â | Â | Â | Â | Â |
FEV1 - % predicted (SD) | 59.3 (23.3) | 66 | 57.3 (22.7) | 54 | 68.3 (24.9) | 12 | 0.178 |
Weight – mean (SD), kg | 66.1 (14.6) | 66 | 63.9 (11.9) | 54 | 76.0 (21.2) | 12 | 0.079 |
BMI – mean (SD), kg/m2 | 23.4 (4.3) | 66 | 22.8 (3.5) | 54 | 26.2 (6.4) | 12 | 0.099 |
BMI < 18.5 | 9 (13.6) | 66 | 7 (13.0) | 54 | 2 (16.7) | 12 | 0.663b |
BMI 18.5–24.99 | 38 (57.6) | 66 | 34 (63.0) | 54 | 4 (33.3) | 12 | 0.104b |
BMI 25–29.99 | 13 (19.7) | 66 | 11 (20.4) | 54 | 2 (16.7) | 12 | 1.000b |
BMI ≥ 30 | 6 (9.1) | 66 | 2 (3.7) | 54 | 4 (33.3) | 12 | 0.008 b |
BMI meeting CFF goala | 38 (57.6) | 66 | 29 (53.7) | 54 | 9 (75.0) | 12 | 0.177b |
CF-related diabetes on insulin | 15 (23.1) | 65 | 14 (26.4) | 53 | 1 (8.3) | 12 | 0.267b |
CF-related PI on enzymes | 58 (89.2) | 65 | 52 (98.1) | 53 | 6 (50.0) | 12 | < 0.001 b |
Prednisone use (at time of survey) | 5 (7.7) | 65 | 5 (9.4) | 53 | 0 (0) | 12 | 0.575b |
PEG tube in place | 2 (3.1) | 65 | 1 (1.9) | 53 | 1 (8.3) | 12 | 0.338b |
Nutritional supplement use | 32 (49.2) | 65 | 26 (49.1) | 53 | 6 (50.0) | 12 | 0.953 |